Preferência por estratos florestais e por substâncias odoríferas em abelhas Euglossinae (Hymenoptera, Apidae) Stratification and scents baits preferences in Euglossinae bees (Hymenoptera, Apidae)

<abstract language="eng">Euglossinae bees of two areas of Terra Firme forest, near Manaus, Amazonas, Brazil were studied. During one year the collections were done fortnightly, using traps with eight kinds of scent baits. The traps were placed in the understory and in tree crowns. Some species showed a very clear vertical stratification in the forest. The comparison between the strata studied showed that the fauna of one understory is more similar to other than fauna of crowns and the similarity between fauna of understory and fauna of crown of the the two areaswas low. Some species were specialists while most were generalists in their choice of scent baits. Some species varied its preferences during the year

Variation in daily flight activity and foraging patterns in colonies of uruçu - Melipona scutellaris Latreille (Apidae, Meliponini)

The flight activities of five colonies of Melipona (Michmelia) scutellaris Latreille, 1811 kept among mixed fruit crop plantations in within fragments of Atlantic Rainforest in Pernambuco, NE-Brazil was examined. The daily deployment of foragers to collect pollen, nectar, resin and mud was observed. The colonies performed between 2,640 and 14,250 flights per day. Variations in the number of total daily flights were similar between colonies on all observation days. Proportional allocation of foragers to the different resources also among colonies showed similar variation. More than 90% of the pollen collection flights were made early in the morning. Nectar was collected in similar proportional frequencies with a reduction in activity at noon. On a single day, was observed atypical intense pollen foraging during the afternoon by all colonies. This indicates a high plasticity in foraging behaviour and efficient recruitment to resources which are presented by mass flowering trees with synchronised big bang or multiple bang flowering. Resource availability of the surrounding vegetation, therefore, seems to be the major factor in defining the forager activities on a given day

Predictors for anastomotic leak, postoperative complications, and mortality after right colectomy for cancer: Results from an international snapshot audit

Background: A right hemicolectomy is among the most commonly performed operations for colon cancer, but modern high-quality, multination data addressing the morbidity and mortality rates are lacking. Objective: This study reports the morbidity and mortality rates for right-sided colon cancer and identifies predictors for unfavorable short-term outcome after right hemicolectomy. Design: This was a snapshot observational prospective study. Setting: The study was conducted as a multicenter international study. Patients: The 2015 European Society of Coloproctology snapshot study was a prospective multicenter international series that included all patients undergoing elective or emergency right hemicolectomy or ileocecal resection over a 2-month period in early 2015. This is a subanalysis of the colon cancer cohort of patients. Main Outcome Measures: Predictors for anastomotic leak and 30-day postoperative morbidity and mortality were assessed using multivariable mixed-effect logistic regression models after variables selection with the Lasso method. Results: Of the 2515 included patients, an anastomosis was performed in 97.2% (n = 2444), handsewn in 38.5% (n = 940) and stapled in 61.5% (n = 1504) cases. The overall anastomotic leak rate was 7.4% (180/2444), 30-day morbidity was 38.0% (n = 956), and mortality was 2.6% (n = 66). Patients with anastomotic leak had a significantly increased mortality rate (10.6% vs 1.6% no-leak patients; p 65 0.001). At multivariable analysis the following variables were associated with anastomotic leak: longer duration of surgery (OR = 1.007 per min; p = 0.0037), open approach (OR = 1.9; p = 0.0037), and stapled anastomosis (OR = 1.5; p = 0.041). Limitations: This is an observational study, and therefore selection bias could be present. For this reason, a multivariable logistic regression model was performed, trying to correct possible confounding factors. Conclusions: Anastomotic leak after oncologic right hemicolectomy is a frequent complication, and it is associated with increased mortality. The key contributing surgical factors for anastomotic leak were anastomotic technique, surgical approach, and duration of surgery

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)